



4-27-05

JFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/825,911
	Filing Date	April 16, 2004
	First Named Inventor	Xinli LIN
	Art Unit	1652
	Examiner Name	R. Prouty
Total Number of Pages in This Submission	8+11 References	Attorney Docket Number 544112000200

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	PTO/SB/08/a/b + copy (4 pages)
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	References (11)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	Return Receipt Postcard
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Jie Zhou		
Date	April 25, 2005	Reg. No.	52,395

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 336621968 US in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 25, 2005

Signature:

(Georgina Matos)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 336621968 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 25 2005

Signature:

Georgina Matos
(Georgina Matos)

Patent

Docket No. 544112000200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of:
Xinli LIN

Serial No.: 10/825,911

Filing Date: April 16, 2004

For: METHODS FOR PRODUCTION OF
RECOMBINANT UROKINASE

Examiner: R. Prouty

Group Art Unit: 1652

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 544112000200.

Dated: April 25, 2005

Respectfully submitted,

By 

Jie Zhou

Registration No.: 52,395
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5922



ALTERNATIVE TO PTO/SB/08 a/b (06-03)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/825,911
				Filing Date	April 16, 2004
				First Named Inventor	Xinli LIN
				Art Unit	1652
				Examiner Name	R. Prouty
Sheet	1	of	2	Attorney Docket Number	544112000200

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2001/0044521-A1	11-22-2001	Lin	
	2.	US-2003/0170242-A1	09-11-2003	Li et al.	
	3.	US-2003/0199676-A1	10-23-2003	Lin	
	4.	US-4,511,503	04-16-1985	Olson et al.	
	5.	US-4,599,197	07-08-1986	Wetzel	
	6.	US-5,188,829-A	02-23-1993	Kobayashi et al.	
	7.	US-5,219,569-A	06-15-1993	Blaber et al.	
	8.	US-5,472,692-A	12-05-1995	Liu et al.	
	9.	US-6,583,268-B2	06-24-2003	Lin	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	10.	WO-01/55174-A2	08-02-2001	Oklahoma Medical Research Foundation		
	11.	WO-03/039491-A2	05-15-2003	Georgetown University		
	12.	WO-2004/094344-A2	11-04-2004	Proteomtech, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	13.	Adams, D.S. et al. (May 5, 1991). "A Synthetic DNA Encoding a Modified Human Urokinase Resistant to Inhibition by Serum Plasminogen Activator Inhibitor," <i>The Journal of Biological Chemistry</i> 266(13):8476-8482.		
	14.	Liu, J.-N. et al. (2002). "Prourokinase Mutant That Induces Highly Effective Clot Lysis Without Interfering With Hemostasis," <i>Circ. Res.</i> 90:757-763.		
	15.	Orsini, G. et al. (1991). "Efficient Renaturation And Fibrinolytic Properties Of Prourokinase And A Deletion Mutant Expressed In <i>Escherichia Coli</i> As Inclusion Bodies," <i>Eur. J. Biochem.</i> 195:691-697.		
	16.	Quax, P.H.A. et al. (1998). "Binding of Human Urokinase-Type Plasminogen Activator to Its Receptor," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> 18:693-701.		
	17.	Sun, Z. et al. (September 19, 1997). "Identification of a Flexible Loop region (297-313) of Urokinase-type Plasminogen Activator, Which Helps Determine Its Catalytic Activity," <i>The Journal of Biological Chemistry</i> 272(38):23818-23823.		
	18.	Tang, W. et al. (1997). "An Efficient System for Production of Recombinant Urokinase-Type Plasminogen Activator," <i>Protein Expression and Purification</i> 11:279-283.		
	19.	Wang, P. et al. (2000). "Catalytic and Fibrinolytic Properties of Recombinant Urokinase Plasminogen Activator from <i>E. coli</i> , Mammalian, and Yeast Cells," <i>Thrombosis Research</i> 100:461-467.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 974301

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/825,911
				Filing Date	April 16, 2004
				First Named Inventor	Xinli LIN
				Art Unit	1652
				Examiner Name	R. Prouty
Sheet	2	of	2	Attorney Docket Number	544112000200

	20.	Winkler, M.E. et al. (1986). "Purification and Characterization of Recombinant Single-Chain Urokinase Produced in <i>Escherichia coli</i> ," <i>Biochemistry</i> 25:4041-4045.	
--	-----	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-974301